Prelude Therapeutics Incorporated

NasdaqGS:PRLD Stock Report

Market Cap: US$71.5m

Prelude Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:PRLD Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
19 Dec 24BuyUS$99,326Krishna VaddiIndividual106,888US$0.93
19 Dec 24BuyUS$22,638Bryant LimIndividual25,000US$0.91

Insider Trading Volume

Insider Buying: PRLD insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of PRLD?
Owner TypeNumber of SharesOwnership Percentage
General Public2,520,1174.58%
Individual Insiders3,277,5405.96%
Institutions11,588,05421.1%
VC/PE Firms16,589,44230.1%
Hedge Funds21,060,01738.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 93.12% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
31.4%
Baker Bros. Advisors LP
17,293,897US$22.5m0%0.15%
30.1%
OrbiMed Advisors LLC
16,589,442US$21.6m0%0.21%
6.84%
Deerfield Management Company, L.P. Series C
3,766,120US$4.9m-8.88%0.06%
3.93%
Krishna Vaddi
2,163,369US$2.8m0%no data
3.1%
Tavistock Life Sciences
1,708,187US$2.2m-33.5%0.11%
2.51%
T. Rowe Price Group, Inc.
1,379,182US$1.8m54.7%no data
1.92%
BlackRock, Inc.
1,058,316US$1.4m-0.99%no data
1.86%
The Vanguard Group, Inc.
1,021,770US$1.3m1.11%no data
1.67%
ExodusPoint Capital Management, LP
921,621US$1.2m0%0.01%
1.62%
Avidity Partners Management, L.P.
890,000US$1.2m0%0.05%
1%
Blue Sky Trust, Endowment Arm
551,776US$717.3k0%no data
1%
Massachusetts Financial Services Company
549,530US$714.4k5.2%no data
0.91%
Paul Friedman
500,098US$650.1k0%no data
0.71%
Geode Capital Management, LLC
391,716US$509.2k8.22%no data
0.65%
Marshall Wace LLP
359,137US$466.9k0%no data
0.59%
Morgan Stanley, Investment Banking and Brokerage Investments
321,966US$418.6k12.8%no data
0.57%
Andrew Combs
312,048US$405.7k0%no data
0.52%
State Street Global Advisors, Inc.
286,046US$371.9k35.1%no data
0.36%
Renaissance Technologies LLC
196,900US$256.0k-4.7%no data
0.33%
Peggy Scherle
180,685US$234.9k0%no data
0.32%
Bridgeway Capital Management, LLC
176,100US$228.9k42.5%no data
0.32%
Jacobs Levy Equity Management Inc
174,979US$227.5k885%no data
0.29%
TD Asset Management, Inc.
160,652US$208.8k0%no data
0.29%
Millennium Management LLC
160,524US$208.7k0%no data
0.24%
Charles Schwab Investment Management, Inc.
133,249US$173.2k4.07%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 12:07
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Prelude Therapeutics Incorporated is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Tazeen AhmadBofA Global Research
Graig SuvannavejhGoldman Sachs